About Asensus Surgical TransEnterix, which rebranded as Asensus Surgical in 2021, pursued the goal of challenging Intuitive Surgical in the robotic surgery market. After the FDA rejected its SurgiBot system in 2016, the company pivoted to the Senhance platform, a digital laparoscopy system featuring haptic feedback and eye-tracking camera control.

Read the full article at ransomware.live →